Table 1 Demographic and other characteristics of study participants
Characteristic | Treatment arm | ||||
|---|---|---|---|---|---|
Placebo | 50 mg EFV | 200 mg EFV | |||
Patient ID | 502–204 | 502–201 | 502-207a | 501–110 | 502–202 |
Age (years) | 71 | 79 | 86 | 71 | 86 |
Gender | M | M | F | F | M |
Race | W | W | W | W | B |
MMSE score before treatment | 27 | 25 | 26 | 22 | 16 |
APOE isoform status | ε3ε4 | ε3ε4 | ε3ε3 | ε3ε4 | ε4ε4 |
CYP46A1 rs754203 (intron-2 T > C) | + / − | − / − | − / − | − / − | − / − |
CYP2B6 rs3745274 (516G > T) | − / − | + / − | − / − | + / + | − / − |
Statin use | Atorv, 10 mg/day | Atorv, 40 mg/day | No | No | No |